UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade
University of California, Davis
University of California, Davis
M.D. Anderson Cancer Center
University of Southern California
Memorial Sloan Kettering Cancer Center
DEKA Biosciences
University of Wisconsin, Madison
Memorial Sloan Kettering Cancer Center
Providence Health & Services
University College, London